Literature DB >> 10942390

Combinations of 4 mutations (FV R506Q, FV H1299R, FV Y1702C, PT 20210G/A) affecting the prothrombinase complex in a thrombophilic family.

E Castoldi1, P Simioni, M Kalafatis, B Lunghi, D Tormene, D Girelli, A Girolami, F Bernardi.   

Abstract

The study of the molecular bases of thrombophilia in a large family with 4 symptomatic members is reported. Three thrombophilic genetic components (FV R506Q, FV H1299R, and PT 20210G/A), all affecting the activity of the prothrombinase complex, were detected alone and in combination in various family members. In addition, a newly identified missense mutation (factor V [FV] Y1702C), causing FV deficiency, was also present in the family and appeared to enhance activated protein C (APC) resistance in carriers of FV R506Q or FV H1299R by abolishing the expression of the counterpart FV allele. The relationships between complex genotypes, coagulation laboratory findings, and clinical phenotypes were analyzed in the family. All symptomatic family members were carriers of combined defects and showed APC resistance and elevated F1 + 2 values. Evidence for the causative role of the FV Y1702C mutation, which affects a residue absolutely conserved in all 3 A domains of FV, factor VIII, and ceruloplasmin, relies on (1) the absolute cosegregation between the mutation and FV deficiency, both in the family and in the general population; (2) FV antigen and immunoblot studies indicating the absence of Y1702C FV molecules in plasma of carriers of the mutation, despite normal levels of the FV Y1702C messenger RNA; and (3) molecular modeling data that support a crucial role of the mutated residue in the A domain structure. These findings help to interpret the variable penetrance of thrombosis in thrombophilic families and to define the molecular bases of FV deficiency. (Blood. 2000;96:1443-1448)

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10942390

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  6 in total

1.  The association between thrombophilic gene mutations and recurrent pregnancy loss.

Authors:  Ahmad Poursadegh Zonouzi; Nader Chaparzadeh; Saeid Ghorbian; Mahzad Mehrzad Sadaghiani; Laya Farzadi; Alieh Ghasemzadeh; Taiebeh Kafshdooz; Masoud Sakhinia; Ebrahim Sakhinia
Journal:  J Assist Reprod Genet       Date:  2013-08-29       Impact factor: 3.412

2.  Functional polymorphisms of FGA, encoding alpha fibrinogen, are associated with susceptibility to venous thromboembolism in a Taiwanese population.

Authors:  Yu-Lin Ko; Lung-An Hsu; Tsu-Shiu Hsu; Chia-Ti Tsai; Ming-Sheng Teng; Semon Wu; Chi-Jen Chang; Ying-Shiung Lee
Journal:  Hum Genet       Date:  2005-12-14       Impact factor: 4.132

3.  Polymorphisms in factor V and antithrombin III gene in recurrent pregnancy loss: a case-control study in Indian population.

Authors:  Amit Sharma; Teena Bhakuni; Ravi Ranjan; Ravi Kumar; Kamal Kishor; Vineet Kumar Kamal; Manoranjan Mahapatra; Mohamad Aman Jairajpuri; Renu Saxena
Journal:  J Thromb Thrombolysis       Date:  2015-05       Impact factor: 2.300

4.  Analysis of factor V in zebrafish demonstrates minimal levels needed for early hemostasis.

Authors:  Angela C Weyand; Steve J Grzegorski; Megan S Rost; Kari I Lavik; Allison C Ferguson; Marzia Menegatti; Catherine E Richter; Rosanna Asselta; Stefano Duga; Flora Peyvandi; Jordan A Shavit
Journal:  Blood Adv       Date:  2019-06-11

5.  A Multiplex Allele Specific Polymerase Chain Reaction (MAS-PCR) for the Detection of Factor V Leiden and Prothrombin G20210A.

Authors:  Morteza Bagheri; Isa Abdi Rad
Journal:  Maedica (Buchar)       Date:  2011-01

6.  A novel factor V mutation causes a normal activated protein C ratio despite the presence of a heterozygous F5 R506Q (factor V Leiden) mutation.

Authors:  Florian Prüller; Reinhard B Raggam; Harald Mangge; Martie Truschnig-Wilders; Eva-Maria Matzhold; Eva-Christine Weiss; Barbara Hasiba; Kelli L Summers; Wilfried Renner; Gabriele Siegert; Heike Kostka
Journal:  Br J Haematol       Date:  2013-08-19       Impact factor: 6.998

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.